""starting points"" with more than a 20 fold advantage over traditional pharmaceutical drug discovery approaches. Already having developed an in-house library of 400 million original molecules and with the value of its capabilities independently recognized by 4 scientific Grants in both the USA and Europe, Carmolex is a 'diamond in the rough.'

With a risk adjusted, net present value of over $60 million, Carmolex is now beginning to commercialize its very efficient drug discovery Services and poised to ?further develop an? internal pipeline of ""hot"" disease related treatment targets. On the shoulders of over $6 million in R&D funding, it is projected that within two years strategic partnerships with large pharma could result in up-front payments, per individual project, in the range of $25 million. Beyond that, upon FDA approvals, royalty agreements that could exceed hundreds of millions for years to come are possible.

Carmolex is important because big? pharma is finding it difficult to refill its new drug pipelines as more of their billion dollar block buster patents expire. In today's much more challenging business and scientific environment, Carmolex's rational, highly targeted approach is key because it's designed to deliver ""personalized medicine"" solutions. Carmolex provides ?those who are visionary with? the opportunity to both profit and make life changing differences for all of us who will eventually be faced by ?cancer, infection, respiratory problems, allergy, arthritis, dementia and other diseases?. Carmolex is prepared to offer 15% of its stock for $3 million.